HQL Overview

abrdn Life Sciences Investors (the Fund), formerly Tekla Life Sciences Investors, is a non-diversified closed-end management investment company. The Fund's investment objective is long-term capital appreciation through investment in United States and foreign companies in the life sciences industry, including biotechnology, pharmaceutical, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information technology and services, devices and supplies, and agriculture and environmental management. The Fund invests primarily in securities of public and private companies, which have the potential for above-average growth. The Fund invests up to 20% of its net assets in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan, and securities of United States issuers that are traded primarily in foreign markets. The Fund's investment adviser is abrdn Inc.

Wall Street analysts forecast HQL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for HQL is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Abrdn Life Sciences Investors revenue for the last quarter amounts to NaN USD, decreased

Abrdn Life Sciences Investors. EPS for the last quarter amounts to USD, decreased

Abrdn Life Sciences Investors (HQL) has 0 emplpoyees as of March 22 2026.

Today HQL has the market capitalization of 0.00 USD.